Prioritizing COVID-19 Policies Beyond the Pandemic
Private-Public Partnerships Aim to Tackle COVID-19 Vaccine Inequity, Distribution Disparities
Geisinger’s “Soft Demo” Proves Key for a Successful Clinical Pathways Rollout
Cancer Care From the COVID-19 Front Lines: “Flying by the Seat of Our Pants”
Adapting to Virtual Care at a Large Cancer Clinic During COVID-19
Integrating Remote Symptom Management With ePROs in Cancer Care
Kavita Patel: Drug Pricing, Care Access Priorities in Federal Health Care Policy
Panel: COVID-19 Presents Opportunity to Reform Health Care Payment, Delivery
Dr Sachin Jain Discusses Data's Role in Monitoring Value-Based Payment Models
Regional Payers Outline Challenges, Successes of Telehealth Implementation
Kathleen Sebelius Reflects on the ACA, Potential for Biden Health Reforms
Dr Marcella Nunez-Smith: Accurate Data Are Needed to Improve Health Disparities
ASH 2020: Clinical Updates
ASH 2020: The Next Wave
In Drug Pricing, PBMs Called the “Arsonist and the Firefighter in One”
How Education, Access Can Optimize Value-Based Cancer Care Delivery
As Practices Await OCF Details, the Question of How to Factor in COVID-19 Emerges
Should All Breast Cancer Patients Receive Genetic Testing?
Dr Hope Rugo on the Importance of a Potential Oral Paclitaxel Option in Metastatic Breast Cancer
Dr Gregory Vidal Discusses Use of Patient Registries in Neratinib Study
Genomic Testing, New Treatments, and Biomarkers Advance HR-Positive Breast Cancer Treatment
Oral Paclitaxel and Encequidar Improves PFS, OS in Metastatic Breast Cancer
Dr Lee Schwartzberg Discusses Immunotherapy Approvals in TNBC
A Look at Established, Emerging Biomarkers for I-O Therapy in Breast Cancer
Dr Yuan Yuan on Oral Ipatasertib's Potential in mTNB
Dr Joanne Mortimer Discusses Novel Oral SERD ZN-c5 in ER-Positive Breast Cancer
2020 Brings 3 Drugs: How the Breast Cancer Treatment Landscape Has Evolved
Dr Rachel Jimenez: Risk, Nature of Cardiac Toxicity in Breast Cancer Is Variable
The Role of Race, Ethnicity, and Cancer in the Time of COVID-19
Dr Karl Kilgore: Updated Data Suggest CAR T Costs, Adverse Events Are Decreasing